 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Tuesday
AZILECT: New Analyses Further Support Benefits of Once-Daily AZILECT(R) in the Treatment of Both Early and More Advanced Parkinson's Disease.../MORE: New York Times
New reports of AZILECT(R) (rasagiline tablets) as initial monotherapy, AZILECT(R) as first adjunctive therapy in moderate patients, and AZILECT(R) in combination with other adjunct agents in moderate to advanced patients were presented at the American Neurological Association meeting today. This information was obtained through further analysis of the three pivotal clinical studies in more than 1,500 patients that supported the approval of AZILECT(R) for the symptomatic treatment of Parkinson's disease.
AZILECT(R) as Initial Monotherapy: Pre-specified non-motor endpoints that captured global aspects of patient improvement and treatment response in 404 patients with early Parkinson's disease in the TEMPO trial provided new insight into the effect of once-daily AZILECT(R) in that patient group. AZILECT(R)-treated patients maintained their quality-of-life scores while scores deteriorated in the placebo group. AZILECT(R) 1mg treated patients also experienced significantly more global improvement and the severity of their illness deteriorated less. "These data show that AZILECT(R) is a good choice for initial monotherapy because it is effective in helping manage early PD symptoms and is also generally well tolerated," said John Bertoni, M.D., Ph.D., Creighton University, and lead author of this abstract.
AZILECT(R) as First Adjunct Therapy in Moderate Disease: Once-daily AZILECT(R) (rasagiline tablets) has demonstrated effectiveness in reducing "OFF" time as adjunct therapy to levodopa in both the PRESTO and LARGO studies. The effect of AZILECT(R) on only patients with moderate disease was evaluated by.....
New reports of AZILECT(R) (rasagiline tablets) as initial monotherapy, AZILECT(R) as first adjunctive therapy in moderate patients, and AZILECT(R) in combination with other adjunct agents in moderate to advanced patients were presented at the American Neurological Association meeting today. This information was obtained through further analysis of the three pivotal clinical studies in more than 1,500 patients that supported the approval of AZILECT(R) for the symptomatic treatment of Parkinson's disease.
AZILECT(R) as Initial Monotherapy: Pre-specified non-motor endpoints that captured global aspects of patient improvement and treatment response in 404 patients with early Parkinson's disease in the TEMPO trial provided new insight into the effect of once-daily AZILECT(R) in that patient group. AZILECT(R)-treated patients maintained their quality-of-life scores while scores deteriorated in the placebo group. AZILECT(R) 1mg treated patients also experienced significantly more global improvement and the severity of their illness deteriorated less. "These data show that AZILECT(R) is a good choice for initial monotherapy because it is effective in helping manage early PD symptoms and is also generally well tolerated," said John Bertoni, M.D., Ph.D., Creighton University, and lead author of this abstract.
AZILECT(R) as First Adjunct Therapy in Moderate Disease: Once-daily AZILECT(R) (rasagiline tablets) has demonstrated effectiveness in reducing "OFF" time as adjunct therapy to levodopa in both the PRESTO and LARGO studies. The effect of AZILECT(R) on only patients with moderate disease was evaluated by.....